Drug Trial Radar · NCT04277637
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
437
Actual
Start
Mar 24, 2020
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Feb 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.
Conditions
- Mature B-Cell Malignancies
Interventions
SonrotoclaxDrug
Film-coated tablets administered once daily at a dose as specified in the treatment arm
ZanubrutinibDrug
320 mg daily administered as two 80-mg capsules twice a day (160 mg twice a day) or as four 80-mg capsules once a day (320 mg once a day)
ObinutuzumabDrug
Given as an intravenous infusion administered per label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 30 days after the last dose of study drug, an average of 18 months
- Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 30 days after the last dose of study drug, an average of 18 months
- Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of SonrotoclaxTime frame: Up to 30 days after the last dose of study drug, an average of 18 months
- Part 1, Part 3: Maximum Tolerated Dose (MTD) of SonrotoclaxTime frame: Up to approximately 2 months
- Part 1, Part 3, Part 5: RP2D of SonrotoclaxTime frame: Day 1 to last dose of study drug, an average of 18 months
- Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant eventsTime frame: Up to 30 days after the last dose of study drug, an average of 18 months
- Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTsTime frame: Up to approximately 2 months
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
UCLA Hematologyoncology
Los Angeles, California
Northwestern University
Chicago, Illinois
University of Kansas Medical Center Research Institute
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York
The James Cancer Hospital and Solove Research Institute At Ohio State University
Columbus, Ohio
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania
Md Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Orange Health Service (Central West Cancer Care Centre)
Orange, New South Wales, Australia
Pindara Private Hospital
Benowa, Queensland, Australia
John Flynn Private Hospital
Tugun, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford PK, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Health
Clayton, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Universitatsklinikum Carl Gustav Carus An Der Technischen Universitat Dresden
Dresden, Germany
Ospedale San Raffaele
Milan, Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Italy
Ospedale Santa Maria Della Misericordia
Perugia, Italy
Azienda Unita Sanitaria Locale Di Ravenna
Ravenna, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Centroricerche Cliniche Di Verona Srl
Verona, Italy
North Shore Hospital
Auckland, New Zealand
Auckland City Hospital
Auckland, New Zealand
Wellington Regional Hospital (Ccdhb)
Wellington, New Zealand
Vall D Hebron Institute of Oncology Vhio
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital de La Santa Creu I Sant Pau
Barcelona, Spain
Ico H Duran I Reynals
Barcelona, Spain
Start Madrid Fundacion Jimenez Diaz
Madrid, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.